Monobenzone
Benoquin (monobenzone) is a small molecule pharmaceutical. Monobenzone was first approved as Benoquin on 1982-01-01. It is used to treat vitiligo in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Monobenzone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BENOQUIN | Bausch Health Companies | N-008173 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| vitiligo | EFO_0004208 | D014820 | L80 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
203 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary bladder neoplasms | D001749 | C67 | 2 | 12 | 16 | 2 | 1 | 31 | |
| Glaucoma | D005901 | EFO_0000516 | H40 | 1 | 6 | 3 | 5 | 5 | 17 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | 1 | 2 | — | 3 | 3 | 9 |
| Pterygium | D011625 | H11.0 | 1 | 1 | — | 1 | 2 | 5 | |
| Head and neck neoplasms | D006258 | — | — | 1 | 1 | 1 | 3 | ||
| Presbyopia | D011305 | H52.4 | — | — | — | 3 | — | 3 | |
| Neovascular glaucoma | D015355 | EFO_1001060 | — | 1 | — | 1 | — | 2 | |
| Refractive errors | D012030 | EFO_0003908 | H52.7 | — | — | — | 1 | 1 | 2 |
| Cervical intraepithelial neoplasia | D018290 | D06 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | 1 | 9 | 4 | — | 1 | 14 | ||
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 3 | 7 | 5 | — | 1 | 14 |
| Anus neoplasms | D001005 | EFO_0003835 | C21 | 2 | 7 | 5 | — | — | 12 |
| Neoplasms | D009369 | C80 | 3 | 4 | 3 | — | — | 10 | |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 2 | 5 | 2 | — | 1 | 10 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 4 | 1 | — | — | 6 |
| Lung neoplasms | D008175 | C34.90 | — | 2 | 4 | — | — | 6 | |
| Urologic neoplasms | D014571 | C64-C68 | — | 2 | 3 | — | 1 | 6 | |
| Neoplasm metastasis | D009362 | EFO_0009708 | 1 | 5 | 1 | — | — | 5 | |
| Transitional cell carcinoma | D002295 | 1 | — | 3 | — | 1 | 5 |
Show 14 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Appendiceal neoplasms | D001063 | EFO_0003880 | C18.1 | 2 | 5 | — | — | 1 | 8 |
| Peritoneal neoplasms | D010534 | 2 | 4 | — | — | — | 6 | ||
| Esophageal stenosis | D004940 | K22.2 | — | 1 | — | — | 3 | 4 | |
| Sarcoma | D012509 | — | 3 | — | — | — | 3 | ||
| Gastrointestinal neoplasms | D005770 | C26.9 | 2 | 2 | — | — | — | 3 | |
| Squamous cell carcinoma | D002294 | — | 2 | — | — | — | 2 | ||
| Carcinoma | D002277 | C80.0 | 1 | 1 | — | — | — | 2 | |
| Squamous cell carcinoma of head and neck | D000077195 | — | 2 | — | — | — | 2 | ||
| Esophageal neoplasms | D004938 | C15 | — | 1 | — | — | 1 | 2 | |
| Adenocarcinoma | D000230 | — | 2 | — | — | — | 2 |
Show 16 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | — | — | — | 1 | 3 |
| Myopia | D009216 | H52.1 | 1 | — | — | — | 1 | 2 | |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | 1 | — | — | — | — | 1 |
| Eye diseases | D005128 | EFO_0003966 | H44 | 1 | — | — | — | — | 1 |
| Leukemia | D007938 | C95 | 1 | — | — | — | — | 1 | |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Corneal diseases | D003316 | H18.9 | — | — | — | — | 1 | 1 | |
| Uterine neoplasms | D014594 | EFO_0003859 | C55 | — | — | — | — | 1 | 1 |
| Fallopian tube neoplasms | D005185 | — | — | — | — | 1 | 1 | ||
| Blister | D001768 | — | — | — | — | 1 | 1 | ||
| Iris diseases | D007499 | — | — | — | — | 1 | 1 | ||
| Deglutition disorders | D003680 | HP_0002015 | R13.1 | — | — | — | — | 1 | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | — | 1 | 1 |
| Tracheal stenosis | D014135 | — | — | — | — | 1 | 1 | ||
| Lacrimal duct obstruction | D007767 | — | — | — | — | 1 | 1 | ||
| Keratitis | D007634 | H16 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MONOBENZONE |
| INN | monobenzone |
| Description | Monobenzone is the monobenzyl ether of hydroquinone. It is used as a topical drug for medical depigmentation. It has a role as a melanin synthesis inhibitor, a dermatologic drug and an allergen. It is functionally related to a hydroquinone. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Oc1ccc(OCc2ccccc2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 103-16-2 |
| RxCUI | 17145 |
| ChEMBL ID | CHEMBL1388 |
| ChEBI ID | 34380 |
| PubChem CID | 7638 |
| DrugBank | DB00600 |
| UNII ID | 9L2KA76MG5 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 200 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,489 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more